{"title":"I 期和 II 期感染科维德阳性孕妇的临床概况和妊娠结局--一项比较研究","authors":"Deepthi Ps, Sathiamma. Pk","doi":"10.22159/ajpcr.2024v17i7.51090","DOIUrl":null,"url":null,"abstract":"Objectives: This study aims to assess the clinical features, the impact of coronavirus disease 2019 (COVID-19) infection during pregnancy, and the perinatal and obstetric outcomes in phases I and II.\nMethods: The current study was performed from January 2020 to August 2021 at the Government T D Medical College, Alappuzha. The pregnant women were registered instantly after each infected woman was known as per the inclusion and exclusion criteria. Demographic parameters, related comorbid disorders, intensive care unit admission, and complete treatment details of each woman were noted. Neonatal outcomes were documented.\nResults: There were 254 women in wave 1 and 164 women in wave 2 in the obstetric admissions. Still was seen in 3 cases (wave 1) and 2 cases (wave 2). In both phases, most pregnant women fall under the age category between 21 and 30. Multi-parity was found to be 50.8% in wave 1 women and 59.2% in wave 2 women were common in both waves. The period of gestation and obstetric comorbidities were found to be statistically significant with a p=0.007 (phase I) and 0.008 (phase II).\nConclusion: Pregnancy-related COVID-19 infection may increase the threat of maternal death but has no influence on the morbidity and death of newborns. It is not possible to totally rule out the possibility of maternal-fetal transfer. Every wave of COVID-19 may have different characteristics and severity; therefore, our treatment plans must change. To confirm this transmission, more research or meta-analysis reports are needed.","PeriodicalId":8528,"journal":{"name":"Asian Journal of Pharmaceutical and Clinical Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CLINICAL PROFILE AND PREGNANCY OUTCOMES OF COVID POSITIVE PREGNANT WOMEN IN PHASE I ANDII INFECTION – A COMPARATIVE STUDY\",\"authors\":\"Deepthi Ps, Sathiamma. Pk\",\"doi\":\"10.22159/ajpcr.2024v17i7.51090\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: This study aims to assess the clinical features, the impact of coronavirus disease 2019 (COVID-19) infection during pregnancy, and the perinatal and obstetric outcomes in phases I and II.\\nMethods: The current study was performed from January 2020 to August 2021 at the Government T D Medical College, Alappuzha. The pregnant women were registered instantly after each infected woman was known as per the inclusion and exclusion criteria. Demographic parameters, related comorbid disorders, intensive care unit admission, and complete treatment details of each woman were noted. Neonatal outcomes were documented.\\nResults: There were 254 women in wave 1 and 164 women in wave 2 in the obstetric admissions. Still was seen in 3 cases (wave 1) and 2 cases (wave 2). In both phases, most pregnant women fall under the age category between 21 and 30. Multi-parity was found to be 50.8% in wave 1 women and 59.2% in wave 2 women were common in both waves. The period of gestation and obstetric comorbidities were found to be statistically significant with a p=0.007 (phase I) and 0.008 (phase II).\\nConclusion: Pregnancy-related COVID-19 infection may increase the threat of maternal death but has no influence on the morbidity and death of newborns. It is not possible to totally rule out the possibility of maternal-fetal transfer. Every wave of COVID-19 may have different characteristics and severity; therefore, our treatment plans must change. To confirm this transmission, more research or meta-analysis reports are needed.\",\"PeriodicalId\":8528,\"journal\":{\"name\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Asian Journal of Pharmaceutical and Clinical Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22159/ajpcr.2024v17i7.51090\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Journal of Pharmaceutical and Clinical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22159/ajpcr.2024v17i7.51090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CLINICAL PROFILE AND PREGNANCY OUTCOMES OF COVID POSITIVE PREGNANT WOMEN IN PHASE I ANDII INFECTION – A COMPARATIVE STUDY
Objectives: This study aims to assess the clinical features, the impact of coronavirus disease 2019 (COVID-19) infection during pregnancy, and the perinatal and obstetric outcomes in phases I and II.
Methods: The current study was performed from January 2020 to August 2021 at the Government T D Medical College, Alappuzha. The pregnant women were registered instantly after each infected woman was known as per the inclusion and exclusion criteria. Demographic parameters, related comorbid disorders, intensive care unit admission, and complete treatment details of each woman were noted. Neonatal outcomes were documented.
Results: There were 254 women in wave 1 and 164 women in wave 2 in the obstetric admissions. Still was seen in 3 cases (wave 1) and 2 cases (wave 2). In both phases, most pregnant women fall under the age category between 21 and 30. Multi-parity was found to be 50.8% in wave 1 women and 59.2% in wave 2 women were common in both waves. The period of gestation and obstetric comorbidities were found to be statistically significant with a p=0.007 (phase I) and 0.008 (phase II).
Conclusion: Pregnancy-related COVID-19 infection may increase the threat of maternal death but has no influence on the morbidity and death of newborns. It is not possible to totally rule out the possibility of maternal-fetal transfer. Every wave of COVID-19 may have different characteristics and severity; therefore, our treatment plans must change. To confirm this transmission, more research or meta-analysis reports are needed.